Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
CTNM Stock Chart & Stats
$11.74
-$0.71(-5.12%)
At close: 4:00 PM EST
$11.74
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$3.35 - $15.25
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$449.68M
Enterprise Value-$66.93M
Total Cash (Recent Filing)$182.41M
Total Debt (Recent Filing)$5.49M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 05, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding30,446,112
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-8.50
Enterprise Value/Market Cap-0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit418.29
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
$19.75Price Target Upside68.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Trial OutcomesCTNM reported positive data from the Ph1b PET study of PIPE-791, showcasing high LPA1 receptor occupancy and potential efficacy.
Potential Of PIPE-791PIPE-791 has best-in-class potential, making the IPF opportunity undervalued and could lead to significant upside for the stock.
Strategic Financial ManagementA strategic decision to defer certain clinical studies has extended the company's projected financial runway through 2028, supporting financial stability.
Bears Say
Reduced Stock Price TargetThe RRMS opportunity removal from the model led to a new DCF-based price target of $22, down from $25, indicating diminished expectations.
Risk In PIPE-307 DevelopmentThe study remains risky with only a 35% probability of success for PIPE-307 in major depressive disorder, highlighting uncertainty in outcomes.
Unmet Trial EndpointsContineum shares are trading down modestly after the Phase II VISTA trial of PIPE-307 did not meet its prespecified primary or secondary efficacy endpoints.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $3.35 and its highest was $15.25 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $449.68M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Mar 05, 2026 which is in 70 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Oct 30, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.034.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.42.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 30,446,112 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 4.459%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (68.23% Upside)
$19.75 (68.23% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 20.8%
Last 30 Days ▲ 20.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. Class A (CTNM) is a biotechnology company focused on the development and commercialization of innovative therapies aimed at treating rare and complex diseases. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of novel drug candidates. Contineum Therapeutics leverages cutting-edge technology and advanced scientific methods to address unmet medical needs, striving to deliver transformative treatments to patients worldwide.
CTNM Stock 12 Month Forecast
Average Price Target
$19.75
▲(68.23% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.61%
Insiders
7.55% Mutual Funds
34.58% Other Institutional Investors
54.08% Public Companies and
Individual Investors